ABBOTT PARK, Ill. and SAN
FRANCISCO, Oct. 14, 2019
/PRNewswire/ -- Abbott (NYSE: ABT) and Omada Health announced today
they are partnering to integrate Abbott's revolutionary FreeStyle
Libre system, a continuous glucose monitoring (CGM) technology,
with Omada Health's pioneering digital care program, aiming to
create a new paradigm for people with Type 2 diabetes. More than 30
million Americans are living with diabetes – with roughly 95% of
them living with Type 2 diabetes1 – and many are looking
for simple ways to better manage their condition and overall
health.
"The mission of Omada Health has always been to empower
meaningful, sustainable behavior change for those individuals
living with Type 2 diabetes and other chronic conditions," said
Omada co-founder and chief executive officer Sean Duffy. "Partnering with Abbott to give
individuals access to FreeStyle Libre as part of the Omada program
will deliver a unique combination of personalized human coaching
and technology-enabled care to support those goals."
With a one-second scan using a smartphone over the FreeStyle
Libre sensor worn on the back of the upper arm, users get real-time
glucose readings every minute, historical trends and patterns, and
arrows showing where glucose levels are going without having to
fingerstick.2 The integrated solution with Omada will
provide real-time glucose data and actionable information for
participants to better manage their diabetes and guide personalized
recommendations from their coaches.
"We've seen how FreeStyle Libre transforms lives through its
proven track record in improving health outcomes, and our goal is
to find new ways for even more people with diabetes to benefit from
this technology," said Jared Watkin,
senior vice president, Diabetes Care, Abbott. "Through this
collaboration, we're creating a personalized care experience that
combines Abbott's leading CGM technology with Omada Health's
professional coaching and digital platform – giving people with
Type 2 diabetes actionable information that leads to better
health."
HOW THE PROGRAM WILL WORK
Omada Health will offer the
integrated solution to employers and health plans. People diagnosed
with Type 2 diabetes who are eligible will be guided through a
tailored experience that includes an online physician consultation,
obtaining a prescription of Freestyle Libre and delivery of a
welcome kit that includes the CGM system and a wireless scale.
Abbott and Omada Health's integrated solution is powered by the
companies' proprietary algorithms and analytics and provides
participants with personalized digital care, directly from their
smartphones,3 to help better manage their diabetes.
Participants will be able to track progress and receive proactive,
tailored recommendations from their assigned certified diabetes
educator (CDE) coaches through online chats in Omada's app. The
program also includes interactive educational lessons about
diabetes, support from an online peer group and a tailored action
plan to help the user build long-term healthy habits to achieve
their goals.
"I've worked as a registered dietitian and certified diabetes
educator for more than 10 years," said Danene 'DJ' Moberly,
registered dietitian and CDE coach, Omada Health. "The biggest
barriers to success for my patients have always been immediate
access to a diabetes educator when they need it most and a lack of
accurate glucose and nutrition data so that we can personalize
treatment. It's exciting that this partnership addresses both needs
and will give people living with Type 2 diabetes access to an
unprecedented suite of tools and personalized support to better
manage their condition."
About Omada Health:
Omada is a digital care program
that empowers people to achieve their health goals through
sustainable lifestyle change. Working primarily through health
plans, employers, and integrated health systems, the company
delivers personalized interventions for individuals at risk for, or
dealing with, type 2 diabetes and hypertension, as well as anxiety
and depression. Combining data-powered human coaching, connected
devices, a proprietary technology platform, and curriculum tailored
to an individual's specific conditions and circumstances, Omada has
enrolled more than 250,000 participants to date. Omada partners
include Cigna, Kaiser Permanente, Blue Cross Blue Shield Minnesota,
and other leading health plans. For additional information, please
visit www.omadahealth.com.
About the FreeStyle Libre System:
Abbott's FreeStyle
Libre, the #1 sensor-based glucose monitoring system used
worldwide,4 reads glucose levels through a sensor that
can be worn on the back of the upper arm for up to 14 days,
eliminating the need for fingersticks.2 The FreeStyle
Libre portfolio has changed the lives of more than 1.5 million
people across 46 countries,5 and has secured partial or
full reimbursement in 34 countries, including France, Ireland, Japan, the United
Kingdom, and the U.S.
Abbott's FreeStyle LibreLink app3 enables users to
capture and view their real-time glucose levels, their eight-hour
glucose history and how their glucose is currently changing on
their smartphone. LibreView is a secure cloud-based diabetes
management system that gives people with diabetes and healthcare
professionals clear, easy-to-understand reports from the FreeStyle
Libre system. For more information, please visit
www.freestylelibre.us.
For the U.S., important safety information:
https://www.freestylelibre.us/safety-information.html
About Abbott:
Abbott is a global healthcare leader
that helps people live more fully at all stages of life. Our
portfolio of life-changing technologies spans the spectrum of
healthcare, with leading businesses and products in diagnostics,
medical devices, nutritionals and branded generic medicines. Our
103,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at
www.linkedin.com/company/abbott-/, on Facebook at
www.facebook.com/Abbott and on Twitter @AbbottNews and
@AbbottGlobal.
______________________________
|
1 Centers
for Disease Control and Prevention. Type 2 Diabetes.
https://www.cdc.gov/diabetes/basics/type2.html
|
2
Fingersticks are required for treatment decisions when you see
Check Blood Glucose symbol, when symptoms do not match system
readings, when you suspect readings may be inaccurate, or when you
experience symptoms that may be due to high or low blood
glucose.
|
3 The
FreeStyle LibreLink app is compatible with NFC-enabled
smartphones running Android OS 5.0 or higher and iPhone 7 or later
running iOS 11 or later. Use of the FreeStyle LibreLink app
requires registration with LibreView, a service provided by
Abbott and Newyu, Inc.
|
4 Data on
file, Abbott Diabetes Care. Data based on the number of users
worldwide for the FreeStyle Libre system compared to the number of
users for other leading personal use, sensor-based glucose
monitoring systems.
|
5 Data on
file, Abbott Diabetes Care.
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/abbott-and-omada-health-partner-to-offer-integrated-digital-health-and-coaching-experience-for-people-with-type-2-diabetes-300937581.html
SOURCE Abbott